University announces advancement in canine cancer treatment

The University of Missouri recently shared progress on their work in helping advance ELIAS Animal Health’s treatment for bone cancer in dogs. The canine immunotherapy treatment is now available at MU, as well as at other universities and specialty hospitals across the country. Dr. Jeff Bryan, director of the MU's Comparative Oncology and Epigenetics Laboratory and principal investigator of the clinical trial, said of the treatment, “It’s the first time that dogs with osteosarcoma have experienced prolonged survival without receiving chemotherapy, which is really exciting.” Read the full announcement.

By |2020-02-26T15:08:42-06:00March 3rd, 2019|News|0 Comments

ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs

Olathe, Kan., Oct. 25, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ELIAS Cancer Immunotherapy (ECI®) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days). These results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field safety and efficacy study in early 2019. “We are very encouraged by our osteosarcoma clinical trial results as we move towards commercialization of ECI® for the veterinary community, while continuing to explore our platform technology in other cancers such as lymphoma,” said Noe Reyes, D.V.M., ELIAS medical director. The trial [...]

By |2022-08-04T18:47:03-06:00October 25th, 2018|Press Releases|0 Comments

ELIAS autologous prescription product exceeds expectations for trial safety and efficacy

Olathe, Kan., July 31, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, shared promising preliminary canine osteosarcoma results for its cancer immunotherapy at the 2018 American College of Veterinary Internal Medicine (ACVIM) Forum in June. The study indicated its new ELIAS autologous cancer vaccine, featuring a patented combination of vaccine and T cell infusion approach, demonstrated impressive survival times and minimal side effects. This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been established. The results were presented by Brian Flesner, D.V.M., Dipl. ACVIM-Oncology, University of Missouri, and highlight continued progress within the immunotherapy arena for the treatment of canine cancer. One in four dogs will be impacted by cancer in their lifetimes and cancer is the No. 1 cause of death in [...]

By |2020-02-26T15:09:41-06:00July 31st, 2018|Press Releases|0 Comments

ELIAS Animal Health Cancer Immunotherapy selected for state of the art presentation at VCS Mid‐Year Conference

Olathe, Kan., Feb. 12, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has been selected by the Veterinary Cancer Society (VCS) for a “State of the Art” presentation at its Mid‐Year Conference in Anchorage, Alaska, March 10‐13. The mid‐year conference is focused on immunotherapy. Brenda Phillips, D.V.M., Dipl. ACVIM (Oncology) will present “T cell‐mediated immunotherapy for common canine cancers” during the state of the art presentation on Sunday, March 11. Dr. Phillips is a board‐certified specialist in medical oncology, practicing with Veterinary Specialty Hospital in San Diego, Calif. The clinical process, ongoing trials, management and experiences of this treatment being developed specifically for veterinary use in dogs will be discussed during the 30‐minute presentation. More data from the study is expected to be presented at the ACVIM Forum in June. ELIAS Animal Health has applied for conditional licensure of its [...]

By |2020-02-26T15:10:20-06:00February 12th, 2018|Press Releases|0 Comments
Go to Top